CureDuchenne provided early funding to Entrada Therapeutics. Entrada has received regulatory authorization in Europe to initiate a Phase 1/2 clinical trial of ENTR-601-44 in ambulatory individuals with Duchenne amenable to […]
CureDuchenne was an early funder of Capricor Therapeutics, which has announced completion of a mid-cycle review meeting with the U.S. FDA for their investigational cell therapy, deramiocel, for Duchenne cardiomyopathy. […]
CureDuchenne Training Therapists in China In March 2025, CureDuchenne expanded its commitment to advancing care worldwide as Doug Levine, PT, traveled to China to lead a series of professional education sessions […]
Four-Day Conference Will Feature Leading Experts, Inspirational Speakers, and the Latest Care and Treatment Insights Newport Beach, Calif., April 17, 2025 – CureDuchenne, a global nonprofit committed to finding and funding […]
Premier Wine Tasting and Auction Brought Acclaimed Napa Valley Vintners Together with Miami Philanthropists to Benefit Global Nonprofit CureDuchenne MIAMI, FL, April 16, 2025 – CureDuchenne, a global nonprofit committed to […]
“Vintage Vegas for Duchenne” Gala Featured Casino Games, Cocktails, Gourmet Dining, and More to Help Advance Research for the Rare Disease AUSTIN, Texas., April 15, 2025 – CureDuchenne, a leading […]
Download PDF HERE CHAMPIONS SPONSORSHIP OPPORTUNITIES 2025
Wave Life Science Exon Skipping in Duchenne Wave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study: An update on Wave’s Phase 2 FORWARD-53 trial of WE-N531, Wave’s […]
Napa in Miami 2025 Auction Catalog Bid by proxy by emailing okairy@cureduchenne.org
